Search

Your search keyword '"Alroughani, R. A."' showing total 257 results
Start Over Author "Alroughani, R. A."
257 results on '"Alroughani, R. A."'

2. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Author

Lefort, M., Sharmin, S., Andersen, J. B., Vukusic, S., Casey, R., Debouverie, M., Edan, G., Ciron, J., Ruet, A., De Sèze, J., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Gout, O., Thouvenot, E., Heinzlef, O., Al-Khedr, A., Bourre, B., Casez, O., Cabre, P., Montcuquet, A., Wahab, A., Camdessanché, J. P., Maurousset, A., Ben Nasr, H., Hankiewicz, K., Pottier, C., Maubeuge, N., Dimitri-Boulos, D., Nifle, C., Laplaud, D. A., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand’Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., McCombe, P., Slee, M., Lechner-Scott, J., Turkoglu, R., Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Maimone, D., Skibina, O., Buzzard, K., Van der Walt, A., Karabudak, R., Van Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Koch-Henriksen, N., Sellebjerg, F., Soerensen, P. S., Hilt Christensen, C. C., Rasmussen, P. V., Jensen, M. B., Frederiksen, J. L., Bramow, S., Mathiesen, H. K., Schreiber, K. I., Butzkueven, H., Magyari, M., Kalincik, T., and Leray, E.

Published
2022
Full Text
View/download PDF

3. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Author

Spelman, T, primary, Herring, WL, additional, Acosta, C, additional, Hyde, R, additional, Jokubaitis, VG, additional, Pucci, E, additional, Lugaresi, A, additional, Laureys, G, additional, Havrdova, EK, additional, Horakova, D, additional, Izquierdo, G, additional, Eichau, S, additional, Ozakbas, S, additional, Alroughani, R, additional, Kalincik, T, additional, Duquette, P, additional, Girard, M, additional, Petersen, T, additional, Patti, F, additional, Csepany, T, additional, Granella, F, additional, Grand’Maison, F, additional, Ferraro, D, additional, Karabudak, R, additional, Jose Sa, M, additional, Trojano, M, additional, van Pesch, V, additional, Van Wijmeersch, B, additional, Cartechini, E, additional, McCombe, P, additional, Gerlach, O, additional, Spitaleri, D, additional, Rozsa, C, additional, Hodgkinson, S, additional, Bergamaschi, R, additional, Gouider, R, additional, Soysal, A, additional, Castillo-Triviño, T, additional, Prevost, J, additional, Garber, J, additional, de Gans, K, additional, Ampapa, R, additional, Simo, M, additional, Sanchez-Menoyo, JL, additional, Iuliano, G, additional, Sas, A, additional, van der Walt, A, additional, John, N, additional, Gray, O, additional, Hughes, S, additional, De Luca, G, additional, Onofrj, M, additional, Buzzard, K, additional, Skibina, O, additional, Terzi, M, additional, Slee, M, additional, Solaro, C, additional, Oreja-Guevara, C, additional, Ramo-Tello, C, additional, Fragoso, Y, additional, Shaygannejad, V, additional, Moore, F, additional, Rajda, C, additional, Aguera Morales, E, additional, and Butzkueven, H, additional

Published
2023
Full Text
View/download PDF

7. Migraine misdiagnosis as a sinusitis, a delay that can last for many years.

Author

Goadsby, Peter, Al-Hashel, JY, Ahmed, SF, Alroughani, R, and Goadsby, PJ

Abstract

Sinusitis is the most frequent misdiagnosis given to patients with migraine.Therefore we decided to estimate the frequency of misdiagnosis of sinusitis among migraine patients. The study included migraine patients with a past history of sinusitis. All incl

Published
2013

10. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Author

Spelman T., Herring W. L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V. G., Kalincik T., Butzkueven H., Luca G., UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Spelman T., Herring W.L., Zhang Y., Tempest M., Pearson I., Freudensprung U., Acosta C., Dort T., Hyde R., Havrdova E., Horakova D., Trojano M., De Luca G., Lugaresi A., Izquierdo G., Grammond P., Duquette P., Alroughani R., Pucci E., Granella F., Lechner-Scott J., Sola P., Ferraro D., Grand'Maison F., Terzi M., Rozsa C., Boz C., Hupperts R., Van Pesch V., Oreja-Guevara C., van der Walt A., Jokubaitis V.G., Kalincik T., Butzkueven H., and Luca G.

Subjects
Pharmacology, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Fingolimod Hydrochloride, Cost-Benefit Analysis, Natalizumab, Health Policy, Public Health, Environmental and Occupational Health, Humans, multiple sclerosis, effectiveness, cost, natalizumab, fingolimod, Immunosuppressive Agents
Abstract

Background: Patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies (interferon-based therapies, glatiramer acetate, dimethyl fumarate, and teriflunomide, known collectively as “BRACETD”) often switch to natalizumab or fingolimod. Objective: The aim was to estimate the comparative effectiveness of switching to natalizumab or fingolimod or within BRACETD using real-world data and to evaluate the cost-effectiveness of switching to natalizumab versus fingolimod using a United Kingdom (UK) third-party payer perspective. Methods: Real-world data were obtained from MSBase for patients relapsing on BRACETD in the year before switching to natalizumab or fingolimod or within BRACETD. Three-way-multinomial-propensity-score–matched cohorts were identified, and comparisons between treatment groups were conducted for annualised relapse rate (ARR) and 6-month–confirmed disability worsening (CDW6M) and improvement (CDI6M). Results were applied in a cost-effectiveness model over a lifetime horizon using a published Markov structure with health states based on the Expanded Disability Status Scale. Other model parameters were obtained from the UK MS Survey 2015, published literature, and publicly available UK sources. Results: The MSBase analysis found a significant reduction in ARR (rate ratio [RR]=0.64; 95% confidence interval [CI] 0.57–0.72; p&nbsp

Published
2021

13. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

Author

Terzi, M., Rojas, J. I., Barnett, M., Fragoso, Y., Cartechini, E., Pucci, E., Willekens, B., Butler, E., Blanco, Y., Grigoriadis, N., Van Hijfte, L., Dirks, P., Liu, C., Rouzic, E. Muros-Le, Butzkueven, H., Al-Harbi, T., Laureys, G., Ozakbas, S., Spelman, T., Alroughani, R., Menoyo, J. L. Sanchez, Van Pesch, V., Kalincik, T., Lechner-Scott, J., Van der Walt, A., Grand'Maison, F., Boz, C., Buzzard, K., and Skibina, O.

Published
2022

14. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

Author

Atkins, H., Burman, J., Massey, J., Sutton, I., Withers, B., Macdonell, R., Grigg, A., Torkildsen, O., Bo, L., Lehmann, A., Horakova, D., Havrdova, E., Krasulova, E., Trneny, M., Kozak, T., van der Walt, A., Butzkueven, H., McCombe, P., Van Wijmeersch, B., Buzzard, K., Skibina, O., Lechner-Scott, J., Willekens, B., Barnett, M., Cartechini, E., Ozakbas, S., Alroughani, R., Izquierdo, G., Boz, C., Kalincik, T., Sharman, S., Roos, I., Freedman, M., Eichau, S., Snowden, J., Sharrack, B., Turkoglu, R., Prevost, J., Slee, M., Soysal, A., Khoury, S., Lugaresi, A., Onofrj, M., Grammond, P., Duquette, P., Girard, M., Prat, A., Terzi, M., Patti, F., and Kuhle, J.

Published
2022

15. Emulating randomized clinical trials in relapsing-remitting multiple sclerosis with nonrandomized real-world evidence: an application using data from the MSBase registry

Author

Karabudak, R., Boz, C., Khoury, S., Girard, M., Turkoglu, R., Soysal, A., Alroughani, R., Terzi, M., Horakova, D., Havrdova, E., Ozakbas, S., Ponzano, M., Grammond, P., Yamout, B., Kalincik, T., Prat, A., Eichau, S., Izquierdo, G., Kuhle, J., Patti, F., Lechner-Schott, J., Sormani, M. P., Butzkueven, H., van der Walt, A., and Signori, A.

Published
2022

16. Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis

Author

Coles, A., Daruwalla, C., Shaygannejad, V., Ozakbas, S., Havrdova, E. K., Alroughani, R., Patti, F., Onofrj, M., Eichau, S., Girard, M., Grand'Maison, F., Yamout, B., Sajedi, S. A., Amato, M. P., Altintas, A., Skibina, O., Grammond, P., Butzkueven, H., Maimone, D., Lechner-Scott, J., Soysal, A., John, N., Gerlach, O., Iuliano, G., Foschi, M., Van Pesch, V., Cartechini, E., Kuhle, J., Sa, M. J., Kermode, A., Gouider, R., Hodgkinson, S., McCombe, P., Sanchez-Menoyo, J. L., Singhal, B., Blanco, Y., Hughes, S., McGuigan, C., Taylor, B., Habek, M., Al-Asmi, A., Mihaela, S., Castillo Trivino, T., Al-Harbi, T., Rojas, J. I., Gray, O., Khurana, D., Van Wijmeersch, B., Kalincik, T., and Brown, J. W. L.

Published
2022

17. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Butler, E., Van Pesch, V., Shalaby, N., Kermode, A., Maimone, D., Blanco, Y., Altintas, A., Turkoglu, R., Butzkueven, H., Van der Walt, A., Skibina, O., Buzzard, K., Lechner-Scott, J., Grammond, P., Khoury, S. J., Yamout, B., Grand'Maison, F., Karabudak, R., Amato, M. P., Terzi, M., Duquette, P., Girard, M., Prat, A., Weinstock-Guttman, B., Lugaresi, A., Onofrj, M., Zakaria, M., Boz, C., Eichau, S., Izquierdo, G., Shaygannejad, V., Alroughani, R., Patti, F., Havrdova, E. K., Horakova, D., Ozakbas, S., Sanchez, M. Martinez, Malpas, C., Simpson-Yap, S., Roos, I., Sharmin, S., Sidhom, Y., Gouider, R., Gerlach, O., Soysal, A., Barnett, M., Kuhle, J., Hughes, S., Sa, M. Jose, and Kalincik, T.

Published
2022

18. Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Author

Macdonell, R., Zhu, C., Kalincik, T., Horakova, D., Zhen, Z., Buzzard, K., Skibina, O., Alroughani, R., Izquierdo, G., Eichau, S., Kuhle, J., Patti, F., Grand'Maison, F., Hodgkinson, S., Grammond, P., Lechner-Scott, J., Butler, E., Prat, A., Girard, M., Butzkueven, H., Van der Walt, A., Merlo, D., Monif, M., Jokubaitis, V., Khoury, S. J., Yamout, B., Garber, J., Kermode, A., Van Hijfte, L., Laureys, G., Boz, C., Terzi, M., Prevost, J., Gerlach, O., Van Wijmeersch, B., Barnett, M., Van Pesch, V., Sa, M. Jose, Slee, M., Ozakbas, S., Weinstock-Guttman, B., and Duquette, P.

Published
2022

19. A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis

Author

Skibina, O., Msbase and Danish Sclerosis Registry Study Grp, Msbase and Danish Sclerosis Registry Study Grp, Kalincik, T., Magyari, M., Gray, O., Sellebjerg, F., Soysal, A., Grand'Maison, F., Grammond, P., John, N., Van Hijfte, L., Laureys, G., Terzi, M., Kuhle, J., Lechner-Scott, J., Butzkueven, H., Van der Walt, A., Buzzard, K., Ozakbas, S., Alroughani, R., Boz, C., MacDonnell, G., Hughes, S., and Roos, I.

Published
2022

21. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry

Author

Spitaleri, D., Kuhle, J., Ozakbas, SERKAN, Patti, F., Ampapa, R., Horakova, D., Soysal, A., Butzkueven, H., Spelman, T., Lechner-Scott, J., Yamout, B., Alroughani, R., Terzi, M., Hodgkinson, S., Sanchez-Menoyo, J., Blanco, Y., Van Pesch, V., Van der Walt, A., Kalincik, T., Laureys, G., Wong, S., Tundia, N., Altintas, A., Oh, J., Gerlach, O., Al-Asmi, A., and Macdonell, R.

Published
2022

22. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (vol 208, 106180, 2021)

Author

De Brouwer, E, Becker, T, Moreau, Y, Havrdova, EK, Trojano, M, Eichau, S, Ozakbas, S, Onofrj, M, Grammond, P, Kuhle, J, Kappos, L, Sola, P, Cartechini, E, Lechner-Scott, J, Alroughani, R, Gerlach, O, Kalincik, T, Granella, F, Grand'Maison, F, Bergamaschi, R, Sa, MJ, Van Wijmeersch, B, Soysal, A, Sanchez-Menoyo, JL, Solaro, C, Boz, C, Iuliano, G, Buzzard, K, Aguera-Morales, E, Terzi, M, Trivio, TC, Spitaleri, D, Van Pesch, V, Shaygannejad, V, Moore, F, Oreja-Guevara, C, Maimone, D, Gouider, R, Csepany, T, Ramo-Tello, C, and Peeters, L

Published
2022

23. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry

Author

Horakova, D., Granella, F., Grand-Maison, F., ÖZAKBAŞ, SERKAN, Bergamaschi, R., Ampapa, R., Alroughani, R., Liu, M., Kenney, R., Turkoglu, R., Terzi, M., Spitaleri, D. L. A., Soysal, A., Sola, P., Preiningerova, J. Lizrova, Patti, F., Onofrj, M., Lugaresi, A., Kalincik, T., Ayuso, G. Izquierdo, Galetta, S., Balcer, L., Kister, I., Spelman, T., Madueno, S. Eichau, Ferraro, D., Boz, C., Butzkueven, H., Gomez, J. Cabrera, Cartechini, E., Thorpe, L., Saidha, S., and Van Pesch, V.

Published
2021

24. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort

Author

Sharmin, S., Malpas, C., Izanne Roos, Diouf, I., Alroughani, R., Ozakbas, S., Izquierdo, G., Eichau, S., Horakova, D., Havrdova, E. K., Patti, F., Terzi, M., Boz, C., Yamout, B., Khoury, S. J., Onofrj, M., Lugaresi, A., Altintas, A., Prat, A., Girard, M., Duquette, P., Sa, M. J., Spitaleri, D., Sidhom, Y., Gouider, R., Soysal, A., Turkoglu, R., Amato, M. P., Fragoso, Y., and Kalincik, T.

Published
2021

25. Real-world experience with ocrelizumab in relapsing multiple sclerosis: insights from the MSOCR-R cohort, an MSBase registry sub-study

Author

Sotoca, J., Rojas, J. I., Sanchez Menoyo, J. L., Kermode, A., Barnett, M., Grand'Maison, F., Van Pesch, V., Terzi, M., Van Hijfte, L., Laureys, G., Alroughani, R., van der Walt, A., Kalincik, T., Skibina, O., Buzzard, K., Boz, C., Spelman, T., Butzkueven, H., Ozakbas, SERKAN, Lechner-Scott, J., Muros-Le Rouzic, E., Liu, C., Dirks, P., and Skromne, E.

Published
2021

27. Real-world experience with cladribine in the MSBase Registry

Author

Prevost, J., Van der Walt, A., Kalincik, T., Grand-Maison, F., McCombe, P., Butler, E., Lechner-Scott, J., di Cantogno, E. Verdun, Van Hijfte, L., Laureys, G., Ozakbas, SERKAN, Girard, M., Prat, A., Hodgkinson, S., Spelman, T., Butzkueven, H., Van Pesch, V., Macdonell, R., Oh, J., Alroughani, R., Grammond, P., Sanchez-Menoyo, J. -L., Terzi, M., Duquette, P., Madueno, S. Eichau, Izquierdo, G., Buzzard, K., and Skabina, O.

Published
2021

29. BREMSO: a simple score to predict early the natural course of multiple sclerosis

Author

Bergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., GrandʼMaison, F., Duquette, P., Shaygannejad, V., Alroughani, R., Grammond, P., Boz, C., Iuliano, G., Zwanikken, C., Petersen, T., Lechner-Scott, J., Hupperts, R., Butzkueven, H., Pucci, E., Oreja-Guevara, C., Cristiano, E., Amato, Pia M. P., Havrdova, E., Fernandez-Bolanos, R., Spelman, T., and Trojano, M.

Published
2015
Full Text
View/download PDF

32. Real-world experience with ocrelizumab in the msbase registry

Author

Butzkueven, H., Spelman, T., Ozakbas, S., Kalincik, T., Boz, C., Buzzard, K., Skibina, O., Alroughani, R., Karabudak, R., Walt, A., Lechner-Scott, J., Hodgkinson, S., Laureys, G., Hijfte, L., Terzi, M., Butler, E., Macdonell, R., Patti, F., Pesch, V., Slee, M., Barnett, M., Grammond, P., Prevost, J., Grand-Maison, F., Taylor, B., Allan Kermode, Mccombe, P., Duquette, P., Prat, A., Girard, M., Eichau Madueno, S., Izquierdo, G., Soysal, A., Sanchez-Menoyo, J. L., Sotoca, J., Muros-Le Rouzic, E., and Dirks, P.

Published
2020

33. Pregnancy in a modern day multiple sclerosis cohort: predictors of postpartum relapse and disability progression

Author

Jokubaitis, V., Yeh, W., Widyastuti, P., Stankovich, J., Gresle, M., Havrdova, E. Kubala, Horakova, D., Vodehnalova, K., Ozakbas, S., Madueno, S. Eichau, Duquette, P., Kalincik, T., Patti, F., Boz, C., Terzi, M., Yamout, B., Lechner-Scott, J., Sola, P., Skibina, O., Barnett, M., Onofrj, M., Sa, M. J., Mccombe, P., Grammond, P., Ampapa, R., Grand Maison, F., Bergamaschi, R., Spitaleri, D., Pesch, V., Cartechini, E., Hodgkinson, S., Soysal, A., Saiz, A., Uher, T., Maimone, D., Turkoglu, R., Hupperts, R., Amato, M. P., Granella, F., Eva Kubala Havrdova, Altintas, A., Macdonell, R., Castillo-Trivino, T., Butzkueven, H., Alroughani, R., and Walt, A.

Published
2020

35. Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy

Author

Yeh, W., Widyastuti, P., Walt, A., Stankovich, J., Gresle, M., Havrdova, E., Horakova, D., Vodehnalova, K., Ozakbas, S., Eichau, S., Duquette, P., Kalincik, T., Patti, F., Boz, C., Terzi, M., Yamout, B., Lechner-Scott, J., Sola, P., Skibina, O., Barnett, M., Onofrj, M., Sa, M. J., Mccombe, P., Grammond, P., Ampapa, R., Grand Maison, F., Bergamaschi, R., Spitaleri, D., Pesch, V., Cartechini, E., Hodgkinson, S., Soysal, A., Saiz, A., Uher, T., Maimone, D., Turkoglu, R., Hupperts, R., Amato, M. P., Granella, F., Eva Kubala Havrdova, Altintas, A., Macdonell, R., Castillo-Trivino, T., Butzkueven, H., Alroughani, R., and Jokubaitis, V.

Published
2020

36. of Therapeutic Lag in Relapsing Multiple Sclerosis

Author

Izanne Roos, Frascoli, F., Horakova, D., Havrdova, E. Kubala, Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. Jose, Boz, C., Grand Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D., Pesch, V., Soysal, A., Prevost, J., Olascoaga, J., Aguera-Morales, E., Turkoglu, R., Slee, M., Ramo-Tello, C., Sidhom, Y., Gouider, R., Mccombe, P., Butzkueven, H., Malpas, C., and Kalincik, T.

Published
2020

37. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Author

Sharmin, S., Lefort, M., Andersen, J., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Butzkueven, H., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., Mccombe, P., Slee, M., Lechner-Scott, J., Recai Turkoglu, Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Skibina, O., Solaro, C., Karabudak, R., Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Leray, E., Sorensen, P. S., Sellebjerg, F., Magyari, M., Vukusic, S., and Kalincik, T.

Published
2019

38. Therapeutic lag in relapsing multiple sclerosis

Author

Roos, I., Frascoli, F., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Onofr, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Ozakbas, S., Grammond, P., Sola, P., Ferraro, D., Bergamaschi, R., Boz, C., Cartechini, E., Sa, M. J., Terzi, M., Alroughani, R., Grand Maison, F., Granella, F., Iuliano, G., Hupperts, R., Lechner-Scott, J., Spitaleri, D., Pesch, V., Soysal, A., Prevost, J., Aguera-Morales, E., Olascoaga, J., Recai Turkoglu, Sidhom, Y., Gouider, R., Wijmeersch, B., Butzkueven, H., Malpas, C., and Kalincik, T.

Published
2019

39. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Author

Kalincik, T., Malpas, C. B., Sharmin, S., Izanne Roos, Patti, F., Butzkueven, H., Alroughani, R., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Hupperts, R., Lechner-Scott, J., Sola, P., Ferraro, D., Grammond, P., Csepany, T., Grand Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Wijmeersch, B., Granella, F., Sa, M. J., Bergamaschi, R., Slee, M., Boz, C., Ozakbas, S., Terzi, M., Prevost, J., Solaro, C., Macdonell, R., Cartechini, E., Coles, A., Havrdova, E. K., and Horakova, D.

Published
2019

40. Real-world experience with Ocrelizumab in the MSBase Registry

Author

Patti, F., Eichau, S., Alroughani, R., Terzi, M., Boz, C., Grand'Maison, F., Grammond, P., Kalincik, T., Van Pesch, V., Barnett, M., Kuhle, J., Hodgkinson, S., Skibina, O., Soysal, A., Butler, E., Slee, M., Prevost, J., Laureys, G., Macdonell, R., van Beek, J., Craveiro, L., Wormser, D., Muros-Le Rouzic, E., Lechner-Scott, J., Ozakbas, SERKAN, Butzkueven, H., and Spelman, T.

Published
2019

44. Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); first clinical and radiological delineation cohort

Author

Shosha, E., primary, Al Asmi, A., additional, Nasim, E., additional, Inshasi, J., additional, Jumah, M., additional, Abdulla, F., additional, Al Malik, Y., additional, Althobaiti, A., additional, Alzawahma, M., additional, Alnajashi, H., additional, Falah, M., additional, Al Harbi, A., additional, Althubaiti, I., additional, Alsharooqi, I., additional, Hundallah, K., additional, Al Rasheed, A., additional, AlRoughani, R., additional, and Ahmed, S., additional

Published
2019
Full Text
View/download PDF

47. Predicting long-term sustained disability progression in multiple sclerosis

Author

Sharmin, S., Malpas, C., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Hupperts, R., Alroughani, R., Boz, C., Shaygannejad, V., Pesch, V., Cartechini, E., Kappos, L., Lechner-Scott, J., Bergamaschi, R., Recai Turkoglu, Solaro, C., Ramo-Tello, C., Iuliano, G., Granella, F., Wijmeersch, B., Spitaleri, D., Bolanos, R. F., Slee, M., Mccombe, P., Prevost, J., Ampapa, R., Ozakbas, S., Sanchez-Menoyo, J. L., Soysal, A., Vucic, S., Petersen, T., Verheul, F., Butler, E., Hodgkinson, S., Sidhom, Y., Gouider, R., Butzkueven, H., and Kalincik, T.

Published
2019

48. MS cohorts and treatment utilization in academic centres in the Middle East

Author

Moradi, N., Sharmin, S., Malpas, C., Ozakbas, S., Shaygannejad, V., Alroughani, R., Kalincik, T., and Ondokuz Mayıs Üniversitesi

Abstract

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS -- SEP 11-13, 2019 -- Stockholm, SWEDEN Turkoglu, Recai/0000-0001-9724-851X; Altintas, Ayse/0000-0002-8524-5087 WOS: 000485303101329 … European Comm Treatment & Res Multiple Sclerosis, Congrex Switzerland Ltd

Published
2019

49. Modifiers of the effectiveness of MS immunotherapies

Author

Kalincik, T., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Cartechini, E., Pesch, V., Iuliano, G., Granella, F., Bergamaschi, R., Bolanos, R. F., Spitaleri, D., Slee, M., Vucic, S., Ampapa, R., Mccombe, P., Ramo-Tello, C., Petersen, T., Verheul, F., Prevost, J., Olascoaga, J., Cristiano, E., and Butzkueven, H.

Published
2019

50. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Author

Brown J, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, Onofrj M, De Luca G, Di Tommaso V, Travaglini D, Pietrolongo E, di Ioia M, Farina D, Mancinelli L, Hodgkinson S, Oreja-Guevara C, Boz C, Prevost J, Olascoaga J, Van Wijmeersch B, Barnett M, Verheul F, Rojas J, Spitaleri D, Rio M, Taylor B, Sanchez-Menoyo J, Ramo-Tello C, Solaro C, Csepany T, Iuliano G, Skibina O, Petersen T, Bolanos R, Sidhom Y, Riadh, Vucic S, Macdonell R, Sempere A, Simo M, Kister I, Shuey N, Radek, Dominguez J, Amato M, Saladino M, Kermode A, Butler E, Moore F, Hughes S, McDonnell G, Piroska I, Yamout B, Soysal A, Ozakbas S, Zwanikken C, and MSBase Study Grp

Abstract

IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition. OBJECTIVE To determine the association between the use, the type of, and the timing of DMTs with the risk of conversion to secondary progressive MS diagnosed with a validated definition. DESIGN, SETTING, AND PARTICIPANTS Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remittingMS commencing DMTs (or clinical monitoring) between 1988-2012 with minimum 4 years' follow-up. EXPOSURES The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). MAIN OUTCOME AND MEASURE Conversion to objectively defined secondary progressiveMS. RESULTS Of the 1555 patients, 1123 were female (mean baseline age, 35 years [SD, 10]). Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to secondary progressiveMS than matched untreated patients (HR, 0.71; 95% CI, 0.61-0.81; P

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results